Myriad Genetics Inc: (NASD: MYGN)
$32.19
-0.05 (-0.16%)
Volume 1,151,582
May 23 04:00 PM ET
Zacks Rank: 2-Buy 
| #2 |
Full Company Report
Myriad Genetics, Inc. uses gene-based medicine to develop therapeutic and molecular diagnostic products. They employ a variety of proprietary proteomic technologies to discover disease genes and to understand the role these genes and their related proteins play in the onset and progression of disease. They have integrated these technologies using bioinformatics and robotics systems to conduct their research efforts on a high-throughput basis. This has enabled them to identify numerous proteins as targets for new drugs and molecular diagnostic tests.
General Information
MYRIAD GENETICS
320 WAKARA WAY
SALT LAKE CITY, UT 84108
Phone: NA
Fax: 801-584-3640
Web: http://www.myriad.com
Email: rchamber@myriad.com
| Industry | MED-BIOMED/GENE |
| Sector | Medical |
| Fiscal Year End | June |
| Last Reported Quarter | 03/31/2013 |
| Next EPS Date | 08/13/2013 |
Price and Volume Information
| Zacks Rank |  |
| Yesterday's Close | 32.24 |
| 52 Week High | 34.70 |
| 52 Week Low | 22.02 |
| Beta | 0.32 |
| 20 Day Moving Average | 1,237,334.88 |
| Target Price Consensus | 32.67 |
% Price Change
| 4 Week | 18.62 |
| 12 Week | 27.94 |
| YTD | 21.14 |
Share Information
| Shares Outstanding (millions) | 80.58 |
| Market Capitalization (millions) | 2,597.83 |
| Short Ratio | 6.67 |
| Last Split Date | 03/26/09 |
% Price Change Relative to S&P 500
| 4 Week | 13.13 |
| 12 Week | 17.17 |
| YTD | 3.36 |
Dividend Information
| Dividend Yield | 0.00% |
| Annual Dividend | $0.00 |
| Payout Ratio | 0.00 |
| Change in Payout Ratio | 0.00 |
| Last Dividend Payout / Amount | NA / $0.00 |
EPS Information
| Current Quarter EPS Consensus Estimate | 0.43 |
| Current Year EPS Consensus Estimate | 1.66 |
| Estimated Long-Term EPS Growth Rate | 12.60 |
| Next EPS Report Date | 08/13/2013 |
Consensus Recommendations
| Current (1=Strong Buy, 5=Strong Sell) | 2.18 |
| 30 Days Ago | 2.08 |
| 60 Days Ago | 2.00 |
| 90 Days Ago | 2.00 |
Fundamental Ratios
P/E
| Current FY Estimate | 19.36 |
| Trailing 12 Months | 20.41 |
| PEG Ratio | 1.53 |
Price Ratios
| Price/Book | 3.91 |
| Price/Cash Flow | 22.57 |
| Price / Sales | 4.54 |
Current Ratio
| 03-31-13 | 8.35 |
| 12-31-12 | 10.06 |
| 09-30-12 | 7.59 |
Net Margin
| 03-31-13 | 23.11 |
| 12-31-12 | 22.73 |
| 09-30-12 | 22.58 |
Inventory Turnover
| 03-31-13 | 7.49 |
| 12-31-12 | 6.64 |
| 09-30-12 | 6.31 |
EPS Growth
| vs. Previous Year | 35.29% |
| vs. Previous Quarter | 9.52% |
ROE
| 03-31-13 | 20.35 |
| 12-31-12 | 19.17 |
| 09-30-12 | 18.45 |
Quick Ratio
| 03-31-13 | 8.22 |
| 12-31-12 | 9.83 |
| 09-30-12 | 7.40 |
Pre-Tax Margin
| 03-31-13 | 37.50 |
| 12-31-12 | 37.18 |
| 09-30-12 | 37.10 |
Debt-to-Equity
| 03-31-13 | 0.00 |
| 12-31-12 | 0.00 |
| 09-30-12 | 0.00 |
Sales Growth
| vs. Previous Year | 20.57% |
| vs. Previous Quarter | 4.92% |
ROA
| 03-31-13 | 18.62 |
| 12-31-12 | 17.64 |
| 09-30-12 | 17.02 |
Operating Margin
| 03-31-13 | 23.11 |
| 12-31-12 | 22.73 |
| 09-30-12 | 22.58 |
Book Value
| 03-31-13 | 8.25 |
| 12-31-12 | 8.13 |
| 09-30-12 | 7.78 |
Debt to Capital
| 03-31-13 | 0.00 |
| 12-31-12 | 0.00 |
| 09-30-12 | 0.00 |
